Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.64 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.64 |
| ▸ | BCL2 | P10415 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8077305 | 0.84 | GABRA1 (0.63) | GABRA1GABRB1BCL2MCL1GSK3B | |
| SCHEMBL28078271 | 0.81 | GABRA1 (0.78) | GABRA1GABRB1BCL2MCL1CA1 | |
| SCHEMBL8077322 | 0.80 | GABRA1 (0.72) | GABRA1GABRB1BCL2MCL1CA1 | |
| SCHEMBL8075582 | 0.80 | GABRA1 (0.72) | GABRA1GABRB1BCL2MCL1CA1 | |
| SCHEMBL2410206 | 0.79 | GABRA1 (0.70) | GABRA1GABRB1BCL2MCL1CA1 | |
| SCHEMBL2416215 | 0.79 | GABRA1 (0.70) | GABRA1GABRB1BCL2MCL1CA1 | |
| SCHEMBL2413335 | 0.79 | GABRA1 (0.70) | GABRA1GABRB1BCL2MCL1CA1 | |
| SCHEMBL8075584 | 0.79 | GABRA1 (0.70) | GABRA1GABRB1BCL2MCL1CA1 | |
| SCHEMBL2417465 | 0.79 | GABRA1 (0.70) | GABRA1GABRB1BCL2MCL1CA1 | |
| SCHEMBL29405385 | 0.78 | GABRA1 (1.00) | GABRA1GABRB1BCL2MCL1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2520290-B1 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE LLC (US) | 2014-12-10 | — | — | EP | claimed |
| US-8026275-B2 | Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury | ABRAXIS BIOSCIENCE, LLC (US) | 2011-09-27 | — | — | US | claimed |
| US-20100160448-A1 | COMPOSITIONS, METHODS OF USE AND PREPARATION OF 2,6-DIISOPROPYL PHENOL AND ANALOGS FOR ISCHEMIC INJURY | ABRAXIS BIOSCIENCE, INC. (US) | 2010-06-24 | — | — | US | claimed |
| CN-101184481-A | Compositions of 2, 6-diisopropylphenol and analogs for ischemic injury, methods of use and preparation thereof | AMERICAN BIOSCIENCE INC (US) | 2008-05-21 | — | — | CN | claimed |
| EP-1853240-A2 | COMPOSITIONS, METHODS OF USE AND PREPARATION OF 2,6-DIISOPROPYL PHENOL AND ANALOGS FOR ISCHEMIC INJURY | Abraxis BioScience, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| WO-2006089120-A2 | COMPOSITIONS, METHODS OF USE AND PREPARATION OF 2,6-DIISOPROPYL PHENOL AND ANALOGS FOR ISCHEMIC INJURY | ABRAXIS BIOSCIENCE, INC (US) | 2006-08-24 | — | — | WO | claimed |
| EP-2520290-B1 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE LLC (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2520290-A1 | Propofol analogs, process for their preparation, and methods of use | Abraxis BioScience, LLC (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2520290-A1 | Propofol analogs, process for their preparation, and methods of use | Abraxis BioScience, LLC (US) | 2012-11-07 | — | — | EP | disclosed |
| US-8026275-B2 | Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury | ABRAXIS BIOSCIENCE, LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100160448-A1 | COMPOSITIONS, METHODS OF USE AND PREPARATION OF 2,6-DIISOPROPYL PHENOL AND ANALOGS FOR ISCHEMIC INJURY | ABRAXIS BIOSCIENCE, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7586008-B2 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7586008-B2 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070185217-A1 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185217-A1 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185217-A1 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| EP-1704135-A1 | PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | Abraxis Bioscience, Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006089120-A2 | COMPOSITIONS, METHODS OF USE AND PREPARATION OF 2,6-DIISOPROPYL PHENOL AND ANALOGS FOR ISCHEMIC INJURY | ABRAXIS BIOSCIENCE, INC (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2005063665-A1 | PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063665-A1 | PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160448-A1 | COMPOSITIONS, METHODS OF USE AND PREPARATION OF 2,6-DIISOPROPYL PHENOL AND ANALOGS FOR ISCHEMIC INJURY | FABP7, QSOX1, DDO | GABRA1 2910/4885GABRB1 2235/4885BCL2 173/4885 |
| US-20070185217-A1 | Propofol analogs, process for their preparation, and methods of use | CYP3A5, CYP3A4, GABARAP | GABRA1 32/4885GABRB1 81/4885BCL2 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.